Cellectis (CLLS)

• Market cap: $390M
• 1 day: -3.48%
• 5 days: -2.02%
• 1 month: -8.27%
• 3 months: -23.47%
• 6 months: 45.32%
• Year to date: -19.17%
• 1 year: 191.73%
• 5 years: -82.9%
• 10 years: -83.7%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222